云克注射液联合艾瑞昔布对类风湿性关节炎患者类风湿因子、免疫球蛋白G4及炎症因子水平的影响

Effect of Yunke injection combined with imrecoxib on rheumatoid factor,immunoglobulin G4 and inflammatory factors in patients with rheumatoid arthritis

目的探讨云克注射液联合艾瑞昔布对RA患者类风湿因子(RF)、免疫球蛋白G4(IgG4)及炎症因子水平的影响。方法选取2020年1—12月于本院就诊的80例RA患者作为研究对象,根据不同的治疗方法分为实验组(n=41)和对照组(n=39)。对照组给予甲氨蝶呤治疗,实验组在对照组基础上给予云克注射液联合艾瑞昔布。比较两组临床疗效、治疗前后RF、IgG4、炎症因子[白细胞介素-8(IL-8)、白细胞介素-1β(IL-1β)及肿瘤坏死因子-α(TNF-α)]水平、疼痛程度[视觉模拟评分法(VAS)]、生命质量[健康评估问卷(HAQ)]及不良反应发生情况。结果实验组治疗总有效率为95.12%,明显高于对照组的79.49%,差异有统计学意义(P<0.05)。治疗后,两组RF、IgG4水平均低于治疗前,且实验组低于对照组,差异有统计学意义(P<0.05)。治疗后,两组IL-8、IL-1β、TNF-α水平均低于治疗前,且实验组低于对照组,差异有统计学意义(P<0.05)。治疗后,两组VAS、HAQ评分均低于治疗前,且实验组低于对照组,差异有统计学意义(P<0.05)。两组不良反应发生率比较差异无统计学意义。结论云克注射液联合艾瑞昔布治疗RA疗效显著,可改善患者的RF、IgG4及炎症因子水平,降低患者疼痛程度,提高其生命质量,值得临床推广应用。

Objective To discuss the effects of Yunke injection combined with imrecoxib on rheumatoid factor(RF),immunoglobulin G4(IgG4)and inflammatory factors in patients with rheumatoid arthritis(RA).Methods 80 patients with RA who were treated in the hospital from January to December 2020 were selected as the research subjects,and they were divided into experimental group(n=41)and control group(n=39)according to different treatment methods.The control group was treated with methotrexate,while the experimental group was treated with Yunke injection combined with imrecoxib on the basis of the treatment of control group.The clinical effect,RF,IgG4,inflammatory factors(interleukin-8[IL-8],interleukin-1β[IL-1β]and tumor necrosis factor-α[TNF-α]),pain degree(visual analogue scales[VAS]),quality of life(health assessment questionnaire[HAQ])and the incidence of adverse reactions were compared between the two groups.Results The total effective rate of the experimental group was 95.12%,which was significantly higher than 79.49%of the control group,the difference was statistically significant(P<0.05).After treatment,RF and IgG4 levels in the two groups were lower than before treatment,and the experimental group was lower than the control group,the difference was statistically significant(P<0.05).After treatment,the levels of IL-8,IL-1βand TNF-αin the two groups were lower than before treatment,and the experimental group was lower than the control group,the difference was statistically significant(P<0.05).After treatment,VAS and HAQ scores in the two groups were lower than before treatment,and the experimental group was lower than the control group,the difference was statistically significant(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups.Conclusion Yunke injection combined with imrecoxib has the significant effect in the treatment of RA,can improve the levels of RF,IgG4 and inflammatory factors in patients,reduce the degree of pain in patients,and improve the quality of life,which is worthy of clinical application.